Table 1. Baseline characteristics of all patients, patients with or without KMT2C mutations.
| Overall (n = 221) | KMT2C-WT (n = 205) | KMT2C-mutated (n = 16) | p value | ||
|---|---|---|---|---|---|
| Baseline PSA (median [IQR]) | 100.100 [48.000, 183.000] | 100.100 [47.750, 183.000] | 100.100 [84.787, 123.825] | 0.9722 | |
| Baseline PSA (ng/mL, %) | <100 | 89 (40.27) | 85 (41.46) | 4 (25.00) | 0.3037 |
| ≥100 | 132 (59.73) | 120 (58.54) | 12 (75.00) | ||
| Age (median [IQR]) | 69.000 [62.000, 75.000] | 69.000 [63.000, 75.000] | 65.500 [59.000, 72.000] | 0.3639 | |
| Age (%) | <70 | 128 (57.92) | 119 (58.05) | 9 (56.25) | 1 |
| ≥70 | 93 (42.08) | 86 (41.95) | 7 (43.75) | ||
| De novo metastasis (%) | No | 24 (10.86) | 22 (10.73) | 2 (12.50) | 1 |
| Yes | 197 (89.14) | 183 (89.27) | 14 (87.50) | ||
| PSA response to CAB (%) | <50% | 28 (12.67) | 28 (13.66) | 0 (0.00) | 0.2334 |
| ≥50% | 193 (87.33) | 177 (86.34) | 16 (100.00) | ||
| ISUP grade (%) | <4 | 41 (18.55) | 40 (19.51) | 1 (6.25) | 0.1959 |
| ≥4 | 180 (81.45) | 165 (80.49) | 15 (93.75) | ||
| AR pathway mutations (%) | No | 167 (75.57) | 158 (77.07) | 9 (56.25) | 0.1176 |
| Yes | 54 (24.43) | 47 (22.93) | 7 (43.75) | ||
| Cell cycle pathway mutations (%) | No | 157 (71.04) | 147 (71.71) | 10 (62.50) | 0.62 |
| Yes | 64 (28.96) | 58 (28.29) | 6 (37.50) | ||
| DDR pathway mutations (%) | No | 169 (76.47) | 157 (76.59) | 12 (75.00) | 1 |
| Yes | 52 (23.53) | 48 (23.41) | 4 (25.00) | ||
| MAPK pathway mutations (%) | No | 195 (88.24) | 182 (88.78) | 13 (81.25) | 0.6188 |
| Yes | 26 (11.76) | 23 (11.22) | 3 (18.75) | ||
| NED pathway mutations (%) | No | 209 (94.57) | 193 (94.15) | 16 (100.00) | 0.6727 |
| Yes | 12 (5.43) | 12 (5.85) | 0 (0.00) | ||
| PI3K pathway mutations (%) | No | 186 (84.16) | 174 (84.88) | 12 (75.00) | 0.4922 |
| Yes | 35 (15.84) | 31 (15.12) | 4 (25.00) | ||
| WNT pathway mutations (%) | No | 196 (88.69) | 184 (89.76) | 12 (75.00) | 0.1661 |
| Yes | 25 (11.31) | 21 (10.24) | 4 (25.00) | ||
| Total mutations (%) | No | 94 (42.53) | 94 (45.85) | 0 (0.00) | 0.0009 |
| Yes | 127 (57.47) | 111 (54.15) | 16 (100.00) | ||
Note: PSA: prostate-specific antigen; CAB: combined anti-androgen blockade; ISUP: International Society of Urological Pathology; AR: androgen receptor; DDR: DNA damage response; MAPK: mitogen-activated protein kinase; NED: neuroendocrine differentiation; PI3K: phosphatidylinositol 3-kinase; IQR: interquartile range; WT: wild type.